13:56 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Blocking the ATAD3A-DNM1L interaction for HD

DISEASE CATEGORY: Neurology INDICATION: Huntington disease (HD) Cell culture and mouse studies identified an inhibitor of ATAD3A-DNM1L interaction that could help treat HD. An in vitro assay for proteins that bind DNM1L identified ATAD3A as...
16:12 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and mouse studies suggest treatment with cilnidipine or inhibiting DNM1L could help treat MI. Screening of antihypertensive drugs in primary rat cardiac fibroblasts cultured under hypoxic conditions identified that...
18:28 , Jul 6, 2017 |  BC Week In Review  |  Financial News

Mitoconix raises $20M in series A

On June 27, neurodegenerative company Mitoconix Bio Ltd. (Jerusalem, Israel) raised $20 million in a series A round led by Remiges Ventures. Also participating were OrbiMed, Dementia Discovery Fund, Arix Bioscience plc (LSE:ARIX), RMGP Biopharma...
23:45 , Jun 27, 2017 |  BC Extra  |  Financial News

Mitoconix's series A round brings in $20M

Neurodegenerative company Mitoconix Bio Ltd. (Jerusalem, Israel) said it raised $20 million in a series A round led by Remiges Ventures. Also participating were OrbiMed, Dementia Discovery Fund, Arix Bioscience plc (LSE:ARIX), RMGP Biopharma Fund...
15:55 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) In vitro and mouse studies suggest inhibiting DNM1L could help treat AD. In primary rat hippocampal neurons exposed to β-amyloid oligomers, a DNM1L inhibitor tool compound decreased mitochondrial fragmentation, reactive oxygen...
08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Dynamin 1-like (DNM1L; DRP1) Mouse studies suggest inhibiting DNM1L could help treat PD. In two mouse models of established PD, striatal injection...
07:00 , Aug 4, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Pain Dynamin 1-like (DNM1L; DRP1) Mouse studies suggest DRP1 inhibition could help treat neuropathic pain. In mouse models of neuropathic pain, antisense or pharmacological...
08:00 , Mar 10, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Dynamin 1-like (DNM1L; DRP1) In vitro and mouse studies suggest that decreasing DRP1 activity could help treat HD. In human neurons...
07:00 , Apr 16, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Dynamin 1-like (DNM1L; DRP1) A study in cell culture suggests that blocking S-nitrosylation of DRP1 could help treat...